Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer Landscape

March 12th 2021

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

FDA Approves Tivozanib for Relapsed/Refractory Advanced RCC

March 10th 2021

The FDA has approved tivozanib (Fotivda) for the treatment of adult patients with relapsed/refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.

Roche Withdraws Atezolizumab Prior-Platinum Treated Metastatic Bladder Cancer Indication in the United States

March 8th 2021

Roche has withdrawn atezolizumab from the US market for the treatment of patients with metastatic urothelial carcinoma who had previously received platinum-based therapy.

NEJM Data Underscore Frontline Nivolumab/Cabozantinib Benefit Over Sunitinib in Advanced RCC

March 5th 2021

The combination of nivolumab and cabozantinib showcased significant benefit in terms of progression-free survival, overall survival, and responses vs sunitinib in the frontline treatment of patients with advanced renal cell carcinoma, as was underscored in data from the phase 3 CheckMate-9ER trial.

Dr. Zhang on Emerging Biomarkers of Response to Immunotherapy in RCC

March 1st 2021

Tian Zhang, MD, discusses emerging biomarkers that are helping to guide treatment for patients with renal cell carcinoma.

Cabozantinib/Nivolumab Approaches EU Approval for Frontline Advanced RCC

February 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.

Ilixadencel/Sunitinib Combo Showcases Promising Survival Benefit in mRCC

February 24th 2021

February 24, 2021—The off-the-shelf immune primer ilixadencel in combination with sunitinib showcased an encouraging, clinically meaningful survival benefit when used in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

Biomarker-Guided Therapies, Novel Combos Take Center Stage in Urothelial Carcinoma

February 23rd 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Nichols on Navigating the Nuances of von Hippel-Lindau Disease

February 22nd 2021

In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.

TKI/Immunotherapy Combos Dominate Frontline Metastatic RCC Management

February 22nd 2021

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

Gomella Lauds Breakthroughs in GU Cancers

February 22nd 2021

A recent wave of drug approvals for treating prostate cancer in earlier disease states, coupled with genomic advances, may help pave the way for a shift toward handling the malignancy as a chronic condition.

AstraZeneca Withdraws Durvalumab Advanced Bladder Cancer Indication From US Market

February 22nd 2021

AstraZeneca has voluntarily withdrawn durvalumab from the US market for the treatment of adult patients with locally advanced or metastatic bladder cancer.

NCCN Issues First-Ever Guidance for Pediatric Solid Tumor

February 19th 2021

February 19, 2021 - The National Comprehensive Cancer Network has issued guidelines for the management of children with a rare type of kidney cancer referred to as Wilms Tumor, or nephroblastoma.

Nivolumab/Cabozantinib Combo Joins RCC Lineup

February 19th 2021

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

FDA Approval Sought for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

February 18th 2021

February 18, 2021 - Two supplemental biologics license applications have been submitted to the FDA for enfortumab vedotin-ejfv to convert the agent’s accelerated approval into a regular one and to expand the current label to include patients with locally advanced or metastatic urothelial cancer who had received prior treatment with a PD-1/PD-L1 inhibitor and are not eligible for cisplatin.

Dr. Nichols on the Prognosis of Patients With VHL Disease

February 17th 2021

Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.

FDA Grants Priority Review to Vicineum for High-Risk, BCG-Unresponsive NMIBC

February 17th 2021

February 17, 2021 - The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.